A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Condition:   Non-Small Cell Lung Cancer Interventions:   Drug: Selpercatinib;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Pembrolizumab Sponsors:   Eli Lilly and Company;   Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials